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Robert H. Morris6,7, Martin Graves7, Joshua Kaggie7, Frances Henson3,4 and Alicia J. El Haj1,2
Abstract
Background: Osteochondral injuries represent a significant clinical problem requiring novel cell-based therapies to
restore function of the damaged joint with the use of mesenchymal stromal cells (MSCs) leading research efforts.
Pre-clinical studies are fundamental in translating such therapies; however, technologies to minimally invasively
assess in vivo cell fate are currently limited. We investigate the potential of a MRI- (magnetic resonance imaging)
and superparamagnetic iron oxide nanoparticle (SPION)-based technique to monitor cellular bio-distribution in an
ovine osteochondral model of acute and chronic injuries.
Methods: MSCs were isolated, expanded and labelled with Nanomag, a 250-nm SPION, and using a novel cell-
penetrating technique, glycosaminoglycan-binding enhanced transduction (GET). MRI visibility thresholds, cellular
toxicity and differentiation potential post-labelling were assessed in vitro. A single osteochondral defect was created
in the medial femoral condyle in the left knee joint of each sheep with the contralateral joint serving as the control.
Cells, either GET-Nanomag labelled or unlabelled, were delivered 1 week or 4.5 weeks later. Sheep were sacrificed 7
days post implantation and immediately MR imaged using a 0.2-T MRI scanner and validated on a 3-T MRI scanner
prior to histological evaluation.
Results: MRI data demonstrated a significant increase in MRI contrast as a result of GET-Nanomag labelling whilst
cell viability, proliferation and differentiation capabilities were not affected. MRI results revealed evidence of
implanted cells within the synovial joint of the injured leg of the chronic model only with no signs of cell
localisation to the defect site in either model. This was validated histologically determining the location of
implanted cells in the synovium. Evidence of engulfment of Nanomag-labelled cells by leukocytes is observed in
the injured legs of the chronic model only. Finally, serum c-reactive protein (CRP) levels were measured by ELISA
with no obvious increase in CRP levels observed as a result of P21-8R:Nanomag delivery.
Conclusion: This study has the potential to be a powerful translational tool with great implications in the clinical
translation of stem cell-based therapies. Further, we have demonstrated the ability to obtain information linked to
key biological events occurring post implantation, essential in designing therapies and selecting pre-clinical models.
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Background
The treatment of osteochondral lesions (OCLs) remains
a burdensome clinical problem significantly impacting
the life of the patient with substantial costs to the
health-care system [1]. OCLs present as injuries to the
cartilage surface of an articular joint, penetrating the
subchondral bone [2]. A number of possible aetiologies
have been identified with repetitive micro-trauma as the
leading cause, affecting people of all ages [3–5]. The
likeness of such injuries self-repairing is limited due to
the inherently poor healing capacity of hyaline cartilage
despite evidence of short-term repair responses [6]. If
left untreated, these injuries can progress in severity and
lead to further degeneration of the articular surface, ul-
timately resulting in osteoarthritis (OA). Once an injury
has reached this stage, symptoms and treatment options
become increasingly severe and challenging. Emphasis is
therefore placed on early intervention to prevent pro-
gression of focal lesions to advanced cartilage degener-
ation and OA [7, 8].
Novel cell-based therapies are currently under devel-
opment and aim to address this clinical need with the
use of mesenchymal stromal cells (MSCs) leading re-
search efforts [4]. MSCs are multipotent stem cells res-
iding within specialised 3D microenvironments of
connective tissues which are able to differentiate towards
tissues of the mesenchymal lineage (cartilage, bone and
fat). The premise of osteochondral tissue engineering in-
volves the use of an osteochondral mimicking scaffold
embedded with MSCs which can be implanted directly
to the site of injury to initiate repair [9]. This typically
involves highly invasive and lengthy surgeries to prepare
the injured site for implantation and, as of yet, has failed
to generate adequate clinical outcomes to support clin-
ical adoption. Alternatively, an injectable cell therapy
model whereby MSCs are minimally invasively delivered
to the site of injury could create an appealing treatment
model [6]. In exploring this mode of delivery and opti-
mising towards clinic adoption, it becomes necessary to
gather information on the short-term in vivo events oc-
curring post implantation in terms of accuracy of cell
transplantation, bio-distribution and cell integration
alongside tissue regeneration [10, 11]. In this way, pa-
rameters linked to the risks and successes of such ther-
apies can be evaluated during pre-clinical studies.
Magnetic resonance imaging (MRI)-based cell tracking
techniques have been used across a number of tissue en-
gineering strategies to monitor exogenous cell popula-
tions in vivo [12]. Target cells are labelled with
superparamagnetic iron oxide nanoparticles (SPIONs)
either with or without the use of a transfection agent
prior to implantation to generate negative or hypoin-
tense contrast when MR imaged using T2 or T2* se-
quences [13]. This technique has been used to
minimally invasively monitor the delivery, retention and
engraftment of implanted cell seeded scaffolds in small
animal models of cartilage injury and arthritis [1, 10,
14]. The application of SPIONs in regenerative medicine
is not limited to their use as contrast agents but also ex-
tends to applications of cell activation [15] and
site-specific targeting [16]. To achieve this breadth of
applications, SPION properties and labelling parameters
can be tailored and optimised to suit each technique
[17]. Our group has pioneered a bio-magnetic approach,
magnetic ion channel activation (MICA), using the com-
mercially available SPION, Nanomag, to activate and
drive MSC differentiation towards bone and cartilage
lineages [18, 19].
In this study, we aim to investigate the use of Nano-
mag as a potential MRI contrast agent which can, in
later applications, be used as a dual MRI and activation
agent in orthopaedic therapies. Furthermore, we define a
protocol to successfully label ovine MSCs with Nanomag
using a novel cell-penetrating peptide and a technique
known as glycosaminoglycan-binding enhanced trans-
duction (GET) to enhance Nanomag uptake [20]. Under
these conditions, we demonstrate the feasibility of
short-term tracking of labelled cells by veterinary MRI
scanner whereby cells are minimally invasively delivered.
We further demonstrate how we can use this short-term
method to investigate the behaviour of stem cells follow-
ing MSC therapy for acute and chronic OA models.
Methods
Reagents were purchased from Sigma Aldrich unless
otherwise specified.
Ethics
All in vivo experiments were approved by the UK Home
Office and Local Ethics committee. Methods were con-
ducted in accordance to the UK Home Office Regula-
tions and protocols approved by University of
Cambridge Animal Welfare and Ethical Review Body.
Animals
Six mature female Welsh Mountain Sheep were used in
this study (n = 3 for each model; acute and chronic).
Bone marrow harvest
Autologous MSCs were isolated by bone marrow aspir-
ation from the iliac crest of anaesthetised animals using
a 100-mm 8 Gauge Jamshidi needle (UK Medical Ltd.,
Sheffield, UK). The aspirate was collected in αMEM
containing 10% FBS, 1% L-glutamine (LG), 1% antibiotic
and anti-mycotic (AA) and a heparin sodium solution to
prevent clotting (5000 IU/ml, Wockhardt, Wrexham,
UK). The aspirate was then transported on ice for down-
stream MSC isolation.
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Surgical procedure
The stifle joints of each animal were opened via a para-
patellar approach with the animals under general anaes-
thesia. An 8-mm-diameter, 8-mm-deep, osteochondral
defect was created in the medial femoral condyle (MFC)
in the left stifle joints of each animal under strict asepsis.
The defects were centralised in the medial femoral con-
dyle, aligned with the medial crest of the trochlear
groove and 10mm distal to the condyle groove junction.
After surgery, the joints were closed in routine fashion,
and the animals were allowed to fully bear weight
post-operatively.
Cell delivery
Prior to delivery, GET-Nanomag-labelled cells were
stained with CM-DiI (Molecular Probes, Paisley, UK), a
fluorescent cell tracker, as per manufacturers’ instructions.
107 labelled cells were subsequently re-suspended in 2ml
serum-free media (SFM) containing 1% LG and1% AA
and transported in darkness on ice for subsequent
intra-articular delivery. Cells ± Nanomag were injected
using a 21-g needle into the left and right femoro-patella
joints at different time points as shown in Fig. 1.
Sacrifice
Sheep were sacrificed 7 days post cell implantation using
an overdose of intravenous anaesthetic solution. Legs
were retrieved immediately and frozen for further ana-
lysis (MRI and histology).
Serum collection
Serum was collected from the jugular vein on day 0 and
day 7.
Cell isolation and expansion
Autologous ovine MSCs were isolated by red blood cell
(RBC) lysis treatment. The aspirate was filtered using a
100-μm cell sieve and washed through with SFM prior to
centrifuging at 220 g for 30 min. The supernatant was
carefully removed, replaced with 5 ml of ice-cold RBC
lysis buffer and incubated for a further 3 min at room
temperature with gentle agitation. Lysis buffer was
quenched with 40ml of ice-cold PBS and lysed cells re-
moved by centrifugation (220 g; 5 min). This process was
repeated until a white pellet appeared at which point 3
ml of media (αMEM media, 20% FBS, 1% L-glutamine
and 1% AA) was added and cells transferred to a T25
flask and maintained at 37 °C for 1 week before further
media changes. MSCs were subsequently cultured (37 °C
and 5% CO2) in αMEM expansion media (EM; 10% FBS,
1% L-glutamine and 1% AA) with a single media change
in the first week and two media changes per week there-
after until cell had reached passage 2 for all animal
experiments.
Cell labelling
MSCs were labelled with Nanomag-D (Micromod,
Germany), a commercially available 250-nm SPION with
COOH functionality using the cell-penetrating peptide
P21-8R and GET technology (obtained from the Univer-
sity of Nottingham). Cells were labelled at a ratio of
25 μg of Nanomag (1 mg/ml) per 2 × 105 cells and com-
plexed with 1 μl (1 mM) P21-8R per 50 μg Nanomag
[20]. In brief, MSCs (P2) were seeded in T175 flasks at
80% confluency in EM and allowed to attach overnight.
Media was then replaced with the labelling solution
(consisting of EM and the appropriate amount of
GET-Nanomag) and cells incubated overnight at 37 °C
and 5% CO2 to enable efficient internalisation of Nano-
mag. Following this, cells were washed thoroughly in
PBS (3×) to remove non-internalised Nanomag.
Assessment of Nanomag uptake by Prussian blue staining
Prussian blue is an iron-based stain routinely used to
identify the presence of SPIONs. Here, it was imple-
mented to firstly evaluate the efficiency of the
Fig. 1 Schematic representation of experimental design
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cell-penetrating peptide in mediating Nanomag uptake
and then to compare uptake across six ovine MSC donors.
MSCs were methanol fixed post Nanomag labelling (15
min; RT) then treated with a 1:1 solution of 20% aqueous
HCL (hydrochloric acid) and 10% aqueous potassium
ferrocyanide (20min; RT) (n = 3). Cells were imaged by
light microscopy (EVOS XL Core Cell Imaging System)
with bright blue staining revealing the presence SPIONs.
Particle characterisation
The effect of GET complexing on the hydrodynamic
diameter and zeta potential (charge) of Nanomag was
assessed using the Malvern Zetasizer Nano ZS. For both
charge and size, 10 μl of Nanomag and GET-Nanomag
were re-suspended in water and three consecutive mea-
surements (12–15 subruns per repeat) per sample at
room temperature were taken.
Assessment of cell viability and proliferation post
Nanomag labelling
Live/dead staining was used to evaluate the extent of cell
death post Nanomag and GET-Nanomag labelling (25 μg/
ml Nanomag). Labelled MSCs were cultured for either 24
hrs or 5 days then treated with 1% calcein AM and 2%
propidium iodide prepared in PBS according to the manu-
facturer’s instructions for 45min at 37 °C, whilst protected
from light. Samples were imaged using a UV fluorescent
microscope (Nikon Eclipse Ti-S). For a quantitative assess-
ment of cell health, alamar blue, a metabolic assay, was
carried out according to the manufacturer’s instructions.
Here, cells labelled with 1, 20, 25 and 50 μg/ml of either
Nanomag or GET-Nanomag were assessed at day 0 (pre--
labelling), day 1 and again at day 7 post-labelling for meta-
bolic activity and compared to untreated controls.
Cell characterisation
Ovine MSCs (P3) from each sheep donor (6 in total)
were characterised by their tri-lineage differentiation po-
tential post Nanomag and GET-Nanomag labelling. In
all cases, cells were plated in triplicate (104 cells/cm2 for
osteogenesis and chondrogenesis and 2.5 × 104 cells/cm2
for adipogenesis) and allowed to attach overnight. Cells
were then labelled with 25 μg/ml Nanomag as described
above and treated with the appropriate differentiation
induction media.
Osteogenesis
Osteogenic induction media consisted of low glucose
DMEM (1 g/L), 10% FBS, 1% L-glutamine, 1% AA, 10− 8
mM dexamethasone, 0.8 mM L-ascorbic acid and 10mM
β-glycerophosphate. Cells were cultured for 21 days with
weekly media changes and fixed in 10% neutral buffered
formalin (10 min; RT) for subsequent Alizarin red stain-
ing (1%).
Adipogenesis
Cells were cultured in adipogenic induction media con-
sisting of high-glucose DMEM (4.5 g/L), 1% BSA,
100 μM indomethacin, 1 μm dexamethasone, 0.5 mM
IBMX (3-Isobutyl-1-methylxanthine) and 10 μg/ml insu-
lin for 72 hrs. Cells, thereafter, were cultured in adipo-
genic maintenance media consisting of DMEM (4.5 g/L),
1% BSA and 10 μg/ml insulin for a further 14 days. Cells
were fixed in formalin (10 min: RT), and adipogenesis
was evaluated by Oil Red O staining.
Chondrogenesis
Chondrogenic media consisted of high-glucose DMEM
(4.5 g/L), 1% FBS, 1% L-glutamine, 1% AA, 0.1 μm dexa-
methasone, 50 μg/ml L-ascorbic acid, 10 ng/ml TGF-β1
(Peprotech, UK) and 50mg/ml ITS (insulin, transferrin,
sodium selenite). Media was completely changed every
3 days for 21 days. Chondrogenesis was evaluated histo-
logically by Alcian blue staining. In all cases, control
cells were cultured in proliferation media for the dur-
ation of the protocol.
MRI
In vitro MRI
The in vitro MRI detection threshold was determined as
previously described by Markides et al [10]. In brief,
Nanomag and GET-Nanomag-labelled cells were encapsu-
lated within a 2mg/ml rat tail type I collagen hydrogel
(BD Biosciences, Oxford, UK) and samples MR imaged
using a Brucker 2.3-T animal scanner (Nottingham Trent
University) with a multi-slice multi-spin echo (MSME)
imaging sequence: TR = 5 s, TE =10.173ms, matrix size =
256 × 128, spatial resolution = 0.35 × 0.35mm.
Ex vivo MRI 0.25 T
Joints were imaged with a 0.25-T MRI (Esaote). The fol-
lowing sequences were used: T1 echo train = 1, TR = 0.0
ms, TE = 26.0ms, slice thickness = 2.5mm, dimension
size = 2.5 × 2.5 mm2, matrix size = 256 × 256, T2 echo
train = 8, TR = 0.0ms, TE = 120.0 ms, slice thickness = 4.0
mm, dimension size = 4.4 × 4.4mm2, matrix size = 512 ×
512, 3D T2-weighted hybrid contrast-enhanced (Hyce)
echo train = 1, TR = 0.0ms, TE = 21.1ms, slice thickness =
2.5 × 2.5mm2, dimension size = 2.5 × 2.5mm2, matrix size
512 × 512.
Ex vivo MRI 3 T
Joints were imaged with a 3D multi-echo spoiled
GRE on a 3.0-T MRI (MR750, GE Healthcare), with
matrix size = 512 × 332 × 76, with six echo times
(TEs = 7.0, 12.7, 18.4, 24.1, 29.7, 35.4 ms), dimension
size = 0.37 × 0.37 × 1.5 mm3, field of view = 190 ×
123 × 114 mm3, flip angle = 20°, coil acceleration
(asset) = 2.0, and an asymmetric readout = 0.7.
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Quantification of CRP (c-reactive protein) levels
CRP levels were determined 7 days post cell implantation
and compared to pre-implantation levels to assess im-
mune response associated with GET-Nanomag delivery.
Blood was collected from the jugular vein and decanted
into untreated 20-ml falcon tubes (no anticoagulant) im-
mediately prior to cell delivery (day 0) and upon sacrifice
(day 7). Serum was collected by allowing blood to coagu-
late overnight at 4 °C then centrifuged at 2000 g for 30
min. CRP levels were determined by ELISA (Neo Bio
Labs, USA) according to the manufacturer’s instructions.
Histology
The distal femoral condyle of each animal, the medial
and lateral meniscus and synovial membrane from the
cranial and dorsal aspect of the joint were collected
post-mortem, decalcified using EDTA and paraffin em-
bedded. Seven-micrometre sections were obtained. Sec-
tions were then stained for hematoxylene and eosin
(H&E) to identify tissue structure and Prussian blue to
determine the presence of Nanomag-labelled cells prior
to imaging.
Statistical analysis
GraphPad Prism V6.0 was used for all statistical analysis.
Data is presented as the average value ± standard devi-
ation (S.D.) with statistical significance determined by
t-test or two-way ANOVA as appropriate. In all cases, * is
p < 0.05, ** is p < 0.01, *** is p < 0.001, **** is p < 0.0001
and ns is no significance.
Results
GET peptide complexation promotes enhanced uptake of
Nanomag by oMSCs across multiple sheep donors
Prussian blue staining for iron content was successful in
demonstrating enhanced uptake of Nanomag as a result
of GET complexing, complementing previous work [20].
This is clearly shown as intense regional blue staining
within internal cell compartments as opposed to naked
Nanomag which was located in the extracellular regions
of each cell (Fig. 2Ai). Furthermore, cell morphology
remained unchanged post GET-Nanomag uptake with
similar uptake levels observed within a single culture
well (Fig. 2Aii) and across multiple sheep donors
(Fig. 2B). Complexing Nanomag with GET further
Fig. 2 Assessment of Nanomag uptake, cell morphology and Nanomag properties as a consequence of GET complexing. Prussian blue staining
highlights the presence of iron-based magnetic nanoparticles by blue staining. Ai Prussian blue staining of oMSCs incubated with no SPIONs,
Nanomag only and GET-Nanomag. Aii Prussian blue staining of GET-Nanomag-labelled oMSCs demonstrating similar uptake by all cells within a
single culture well. B Prussian blue staining of GET-Nanomag-labelled MSCs from six sheep donors demonstrate consistent uptake across multiple
donors. Ci Zetapotential measurements of Nanomag and GET-Nanomag determined in water. Cii Hydrodynamic diameter of Nanomag and GET-
Nanomag determined in water. Data in Ci and Cii represents the mean zeta potential (ζ) ± s.d (n = 3) and hydrodynamic diameter ± s.d (n = 3)
respectively with significance determined by unpaired t-test where **** is p < 0.0001. Scale bars = 100 μm
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resulted in a significant change in the charge of the
particle from − 26.86 ± 0.3 to + 7.29 ± 0.1 (p < 0.0001)
(Fig. 2Ci) with no significant influence on the hydro-
dynamic diameter of the particle (Fig. 2Cii).
No adverse effects on cell viability, proliferation and tri-
lineage differentiation potential of oMSCs as a result of
GET-Nanomag labelling
Labelling cells either with or without the addition of the
cell-penetrating peptide had no adverse impact on the
viability of oMSCs in short- (24 hr) and long-term (5
days) cultures as determined by live/dead staining. An
obvious increase in the number and density of cells was
further observed in all cases over a 5-day culture period
implying that labelled cells maintained their ability to
proliferate with results equivalent to unlabelled controls
(Fig. 3A). Quantitative Alamar blue results further sup-
port this data by demonstrating no diminished viability
and proliferation potential (as inferred by metabolic
activity) for cells labelled either with Nanomag or
GET-Nanomag (0, 1, 10, 25 and 50 μg/ml) over 7 days and
compared to unlabelled controls. GET-Nanomag-labelled
oMSCs were further shown to successfully differentiate
towards the osteogenic, adipogenic and chondrogenic lin-
eages when cultured in the relevant differentiation media
in a comparable manner to unlabelled cells (Fig. 3C).
Enhanced MRI contrast observed in vitro as a result of
GET-mediated cell labelling
The in vitro MRI visibility threshold in terms of cell
dose and Nanomag concentration was assessed in a 3D
collagen gel system. Internalised iron-based particles dis-
rupt the local magnetic field causing a shortening of T2*.
Consequently, this creates hypointense regions of signal
void (black areas) on an MRI scan. To quantify this,
measurements of T2
eff are undertaken. T2
eff is a param-
eter which is based on T2* but more easily measured in
the case of short T2* as it relies on the generation of a
number of consecutive spin echoes. In this study, T2
eff
remained long in groups lacking the GET peptide. Fur-
thermore, increasing incubation time (1 to 24 h), in-
creasing cell dose (104–5 × 105 cells per 100 μl collagen
gel) and increasing Nanomag concentration (0–50 μg/
ml) had no significant impact on T2
eff with similar
values measured in the control unlabelled cell groups
(Fig. 4Ai, Ci). This is further observed visually in the
T2
eff plots where the colour intensity from the grey-scale
MRI scans remained unchanged in comparison to the
control unlabelled groups (light grey) (Fig. 4Aii, Cii). In
contrast, a distinct and significant shortening of T2
eff is
measured with increasing incubation time, cell dose and
Nanomag concentration in GET-Nanomag-labelled cell
groups (Fig. 4Bi, Di). This is likely due to the improved
uptake efficiency of Nanomag as a result of the GET
cell-penetrating peptide. Based on the corresponding
T2
eff plots, good contrast was generated (black region)
when labelling 5 × 105 cells with 50 μg/ml GET-
Nanomag over a 1 h incubation period (Fig. 4Bii). These
conditions are improved by increasing the incubation to
24 h resulting in contrast for as low as 104 cells labelled
with 25 μg/ml GET-Nanomag or for 5 × 105 cells labelled
with 10 μg/ml GET-Nanomag (Fig. 4Dii).
Surgical model
Surgery was tolerated well by all sheep without compli-
cations. No signs of an adverse immune reaction to
GET-Nanomag delivery in either model were detected.
C-reactive protein (CRP) levels were measured on day 0
(pre-cell implantation) and upon sacrifice on day 7 in
the chronic model revealing no deviation from baseline
levels (Fig. 5a). Furthermore, comparing CRP levels at
sacrifice in the acute and chronic models revealed no
significant differences. (Fig. 5b).
Ex vivo MRI tracking
Knee joints were MR imaged post sacrifice initially on a
0.25-T veterinary MRI scanner (Fig. 6a) and then vali-
dated on a 3-T clinical MRI scanner (Fig. 6b). Iron-based
magnetic nanoparticles are visualised as hypointense re-
gions of signal void or “black” areas on MRI scans within
the knee joint. In this study, the presence of
GET-Nanomag-labelled cells is clearly visible as “black”
regions (red star) in the injured leg (left knee) of the
chronic model (Fig. 6a (i)) and the control leg (right
knee) of the acute model (Fig. 6a (ii)). On the contrary,
no “black” regions were observed in the injured leg (left
knee) of the acute model (Fig. 6a (ii)) nor in the control
leg (right knee) (Fig. 6a (i)). Finally, labelled cells were
not observed within the osteochondral defect (yellow
arrow) in either model via MRI. Similar results are ob-
served in the left legs of the 3-T images (Fig. 6b).
Histological evaluation
To validate and confirm the location of implanted cells,
histological sections of the osteochondral defect and the
synovium were scrutinised for the presence of
GET-Nanomag-labelled cells. Implanted cells were iden-
tified by red fluorescence significant of the DiI stain used
to label cells pre-delivery whilst Prussian blue staining
was used to identify the iron-based magnetic nanoparti-
cle, Nanomag. H&E staining further revealed key tissue
structures and allowed for the defect and synovium to
be accurately identified. Fibrous tissue is seen to com-
pletely fill each defect of both the chronic and acute
model. The matrix appeared to be denser and more
organised in the chronic model (Fig. 7a (i)).
No evidence of implanted cells was detected in the
osteochondral defect in either model (Fig. 7a (ii), (iii)),
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consistent with MRI results. Instead, labelled cells are
observed within the synovial lining of both the chronic
and acute injury models, evident by the overlaying Prus-
sian blue stain and florescent DiI stain (Fig. 7b (ii), (iii)).
Comparatively, increased cell density is observed in this
region in the injured leg of the chronic model relative to
the acute model (Fig. 7b (iii)) with subsequent localisa-
tion of SPIONs (Fig. 7b (ii)) implying that cells have
retained the SPION label.
On closer inspection of the synovial lining of the
chronic model, significant localisation of labelled cells is
observed in injured leg (left leg) and to a lesser extent in
the non-injured control leg (right leg) (Fig. 8a). In the
acute model, however, areas of higher cell density are
observed in the control leg as opposed to the injured leg
(left leg) (Fig. 8b).
Evidence of co-localisation of CD45-positive leukocytes
and GET-Nanomag is observed in the synovial lining of
injured legs in chronic model only
The presence of leukocytes (white blood cells) was
assessed by immunohistochemical staining for CD45. Leu-
kocytes (stained green) are present in both injury models
with an obvious increase observed in the chronic model
compared to the acute injury model (Fig. 9). Furthermore,
a strong correlation in the localisation of DiI-labelled
MSCs and leukocytes in the chronic injury model is ob-
served, suggesting that GET-Nanomag-labelled MSCs are
potentially engulfed and transported by the leukocytes to
the synovium (Fig. 9a).
Discussion
Despite extensive clinical efforts, cartilage and osteo-
chondral injuries continue to burden the patient and
healthcare system. In light of this, cell-based therapies
have been proposed, offering new opportunities in tack-
ling these conditions. Pre-clinical animal models define
an essential component of the research process and are
implemented to not only investigate the safety and effi-
cacy of proposed therapies but also allude to the
Fig. 3 In vitro assessment of cell viability, proliferation and tri-lineage
differentiation potential post GET-Nanomag labelling of oMSCs. Images
are selected for a single sheep donor but are representative of all
donors. a Live/dead staining of labelled (25 μg/ml) and unlabelled
oMSCs 24 hrs and 5 days post-labelling. b Quantification of cellular
health via Alamar blue metabolic assay at days 0 (pre-labelling), 1 and
7 (post-labelling) with cells labelled with 0, 1, 10, 25 and 50 μg/ml
Nanomag or GET-Nanomag. c Tri-lineage differentiation of labelled
(25 μg/ml) and unlabelled oMSCs from a representative sheep donor
(donor 26) where alizarin red staining was used to confirm
osteogenesis (day 28), Oil Red O staining to assess adipogenesis (day
14) and finally Alcian blue staining to evaluate chondrogenesis (day 21)
(n = 3). GET-Nanomag-labelled cells cultured in basic media served as
representative control groups (n = 3). Scale bars = 100 μm
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mechanisms of action. The need to rapidly and reprodu-
cibly assess optimal delivery routes, cell doses, tissue en-
graftment and cellular bio-distribution patterns, whilst
also complying with the NC3Rs to minimise the number
of animals inflicted, has driven the need for minimally
invasive techniques to monitor in vivo cell fate. The
combined use of magnetic resonance imaging (MRI) and
superparamagnetic iron oxide nanoparticles (SPIONs)
has been proposed as one such minimally invasive strat-
egy [10], the feasibility of which is explored in a osteo-
chondral pre-clinical sheep model and reported in this
manuscript.
SPIONs are well known for their clinical application
as a T2-weighted MRI contrast agent and have been
used in the diagnosis of a wide range of diseases and in-
juries [21]. Early successful adopters of MRI cell track-
ing protocols utilised either Endorem or Resovist both
of which are FDA-approved MRI contrast agents to
label stem cells for follow on MRI tracking in a number
of organs including the articular knee joint [22–25]. As
of 2009, the manufactures of these compounds with-
drew both products from the market siting economic
reasons [24, 26, 27]. As a result, a number of off-label
(e.g. Feraheme), in-house or commercial SPIONs have
been investigated showing promise in tracking cells in a
wide range of clinical indications such as neural regen-
eration, pancreatic islet transplantation and renal re-
generation [28].
Fig. 4 In vitro MRI dose response of Nanomag-labelled MSCs encapsulated in 2.5 mg/ml collagen type 1 gel. A and B are MSCs labelled with
Nanomag for 1 h and 24 hrs respectively. C and D are MSCs labelled with GET-Nanomag for 1 hr and 24 hrs respectively. For each subfigure, i is
the T2
eff measurement produced from the MRI image and ii is the corresponding T2
eff plots. Data represents mean T2
eff values ± s.d. (n = 3) with
significance determined by two-way ANOVA statistical test where * is p < 0.05, ** is p < 0.01, *** is p < 0.001 and **** is p < 0.0001
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For the first time, we introduce the commercially
available SPION, Nanomag-D, as a potential cell track-
ing contrast agent. This particle has been implemented
in the development of a pioneering technique whereby
the particle, Nanomag, is used to remotely activate key
mechanotransduction pathways involved in osteogenic
differentiation of MSCs using an external magnetic field
[15]. This technique, known as magnetic ion channel ac-
tivation (MICA), has recently been employed in a
pre-clinical sheep model of bone injury supporting the
development of an injectable therapy for non-union
bone fractures [19]. In future work, we plan to utilise
MICA in the development of an injectable cartilage re-
pair therapy by introducing mechanical influences other-
wise lacking in standard cartilage therapies. The results
presented in this manuscript are significant in that the
optimal contrast-forming dose of Nanomag (25 μg/ml) is
aligned with in vivo MICA activation doses utilised in the
pre-clinical study [19]. Therefore, Nanomag can poten-
tially be taken forward as a dual MRI and activation agent
and applied to further our understanding of repair mecha-
nisms by mapping the location of Nanomag-labelled cells
relative to repair sights by MRI with little manipulation of
the labelling protocol.
Studies have reported poor cellular uptake of
dextran-coated SPIONs by non-phagocytic cells such as
MSCs thereby limiting their application as MRI cell
tracking agents [29, 30]. In line with our result, we
observe limited uptake of Nanomag, a 250-nm
dextran-coated particle, resulting in poor MRI contrast
in vitro regardless of incubation time and labelling con-
centration. Transfection agents such as poly-L-lysine
(PLL), protamine sulfate and lipofectamine have played a
crucial role in enhancing the uptake of SPIONs (such as
the FDA-approved particles mentioned earlier) to detect-
able levels for MRI tracking applications [29, 31–33].
These cationic compounds function by forming posi-
tively charged complexes with SPIONs to encourage
electrostatic attraction with the negatively charged cell
membrane [31]. Although significant improvements in
uptake efficiency have been reported, these compounds
are associated with dose-dependant toxic effects [30]. In
this study, a novel cell-penetrating peptide P21-8R
intended to enhance the uptake of Nanomag by oMSCs
using a technique known as GET (glycosaminoglycan--
binding enhanced transduction) has been investigated
[20]. The system, developed by our group, functions to
improve the activity of standard cell-penetrating pep-
tides to ultimately enhance intracellular delivery of car-
gos. It involves the interaction of the peptide P21-8R
with cell membrane heparan sulfates to promote endo-
cytosis [20]. We further demonstrate a significantly posi-
tive shift in the charge of Nanomag once complexed
further promoting cell interactions towards improved
uptake. Importantly, this approach is considered safe
and does not affect cell proliferation and viability [20].
Little or no adverse effects have been reported with
SPION labelling in terms of cell proliferation, viability and
differentiation potential. SPION toxicity is often correlated
to dose, composition and the immediate microenviron-
ment of the particle all of which can trigger unwanted
toxic effects either directly to implanted cells or the sur-
rounding tissue [34]. Here we demonstrate no diminished
cell viability, proliferation and differentiation potential
across six sheep donors when labelled with
GET-Nanomag in vitro. Conflicting reports have however
raised concern regarding the chondrogenic differentiation
potential of SPION-labelled MSCs with studies reporting
Fig. 5 Autologous serum CRP levels. a CRP levels in the chronic injury model where levels were measured prior to the delivery and upon
sacrifice in three sheep. b Comparative CRP levels at sacrifice in the acute and chronic models. Data represents mean CRP levels ± s.d. for three
individual sheep with significance determined by unpaired t-test where ns implies no significance
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either impaired chondrogenesis [35–37] or no effect at all
[25, 28]. This is thought to be a dose-dependant effect ac-
counting for the contrasting reports although further ana-
lysis is required [38, 39]. In our study, we observed no
compromised chondrogenesis of autologous oMSCs when
labelled with GET-Nanomag in vitro. Furthermore, CRP
(c-reactive protein) levels in vivo were determined to be
within normal range in both the acute and chronic injury
model implying that the delivery of GET-Nanomag-
labelled cells has not elicited an unwanted short-term im-
mune response. This data provides further support for the
in vivo use of this magnetic particle system in the develop-
ment of an osteochondral therapy.
We report the detection of GET-Nanomag-labelled
MSCs in the articular knee joint of sheep 7 days
post-delivery using a 0.25-T veterinary MRI scanner with
results validated on a 3-T clinical grade scanner post sac-
rifice. Labelled cells are identified as hypointense
regions, made particularly obvious where there are
“blooming” artefacts, a phenomenon whereby the signal
from the SPION extends far beyond the size of the parti-
cles due to the high susceptibility of large concentrations
of ferrous material. This allows for high concentrations
of SPION-labelled cells to be easily and practically iden-
tified against anatomical tissue [10]. MRI results on day
7 revealed no hypointense regions at the OCL injury site
Fig. 6 Cross-sectional MRI images of the knee joints 7 days post cell delivery. a T1 MRI scans obtained using a 0.25-T Esaote MRI scanner and
validated using a b MR750 3-T GE Healthcare scanner with T2 sequences. Red star represents areas of blooming artefact due to the presence of
significant amounts of SPION-labelled cells whilst yellow arrow represents the site of the osteochondral defect and green star the site of the
femoral patella joint. F = femur, T = tibia, M = meniscus, P = patella, FC = femoral condyle
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in either the acute or the chronic injury models implying
that cells have not homed to the site of injury. Further-
more, this technique allows for differences in the distri-
bution patterns of labelled cells between the two models
to be observed. Characteristic hypointense blooming is
seen in the injured leg of the chronic model but not in
the acute model despite detection of cells in the control
leg of the acute model. Although the blooming
phenomenon facilitates easy detection of implanted cells,
it may result in key anatomical structures being lost as
can be seen on the 0.25-T images. This makes it ex-
tremely difficult to determine the exact location of
SPION-labelled cells and is considered a limitation of
the study. To facilitate clinically relevant scan durations,
different protocols are used on the two MRI scanners
resulting in visually different contrast, and marginally
less influence of the blooming artefact at 3 T despite the
higher field. Despite the different weighting of the
images, the effect of the SPIONs is similar since the sig-
nal loss caused by dephasing will dominate most gradi-
ent and spin echo sequences.
We hypothesise that the variations in the distribution
patterns observed in the chronic and acute injury
models are related to the inflammatory environment of
the injured joint. In this case, the creation of the OCL
defect triggers an inflammatory response which is asso-
ciated with the release of inflammatory mediators, en-
hanced cellular infiltration and increased monocyte and
macrophage content. This is greatest in the acute
post-injury period (up to 1 week) but will be sustained at
lower levels thereafter [40]. It is therefore suggested that
the heightened inflammatory environment of the acute
injury results in increased macrophage recruitment
which acts to clear implanted cells prior to sacrifice.
This is corroborated by immunohistochemical analysis
where a distinct lack of CD45-positive leukocytes is
Fig. 7 Representative tissue sections showing a the osteochondral defect and b the synovium from the injured leg (left leg) of both models.
Tissue structure is shown by (i) H&E staining where connective tissue is depicted by pink whilst cellular matter is stained purple, insert; MR image
depicting general location of histological section (defect and synovium). (ii) Prussian blue staining revealed the presence of iron oxide-based
magnetic nanoparticle and is seen as blue staining. (iii) Fluorescent red staining represents delivered oMSCs stained with the membrane dye DiI
prior to delivery. Scale bars = 100 μm. SCB = subchondral bone, FT = fibrous tissue
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observed in the acute model [41]. In the chronic injury
model however, where cells are minimally invasively de-
livered to the knee joint 4.5 weeks post injury when in-
flammatory levels are reduced, cells remain within the
synovial joint as detected by MRI and by histology. This
implies that cells are not cleared from the knee joint and
are instead captured and localised by a complexed com-
munity of macrophages found in the synovium. CD45 is
a transmembrane glycoprotein representative of leuko-
cytes which are typically characterised as white blood
cells or immune cells including macrophages and mono-
cytes and are recruited as part of the inflammatory re-
sponse to injury. In studies investigating the effects of
nanoparticles on the inflammatory process of the articular
knee, it has been shown that nanoparticles are engulfed by
monocytes or macrophages, particularly by those residing
in the synovial lining and have been detected up to 14 days
post intra-articular implantation [42] in a number of small
[43] and large animal studies [44]. Similar observations
are made in this study where Nanomag-labelled cells are
observed along the synovial lining.
The migration and adhesion of MSCs to a cartilage
injury is dependent on multiple factors including the
secretion of chemotactic factors by damaged cartilage
or synovial tissues, the expression of chemotactic re-
ceptors by MSCs, the adherence properties of the tis-
sue/cartilage and the mechanical shear stresses in the
surrounding environment [45]. Whilst studies demon-
strating cell homing to the injury site following in
vivo intra-articular delivery have been reported, it has
Fig. 8 Histological sections of the synovium in the a chronic and b acute injury models with focus on (i) the left injured leg and (ii) the right
non-injured control leg where delivered oMSCs are stained with the membrane dye DiI and are shown by red fluorescent imaging whilst
Prussian blue staining identifies Nanomag and is seen as the black staining in these monochrome images. Scale bars = 100 μm
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been noted that the ratio of cells homed to the de-
sired site is limited. This is a cause of clinical con-
cern as it can impact therapeutic outcome and is
therefore an area of continuous research [46, 47]. It
has been shown that the exposure of MSCs to an in-
flammatory and/ a hypoxic environment can influence
the expression of migratory factors of MSCs [45, 48].
Furthermore, many studies have observed a preferen-
tial accumulation of delivered MSCs to the synovium
which may be due to the release of an alternative
chemotactic release profile [45]. Another explanation
for the observed improved adhesion of MSCs to
the synovium could be that the mechanical forces ex-
perienced in the joint mobilise the MSCs to the syno-
vium and that cells are more likely to attach to a
rough surface like the synovium than to a smooth
surface like cartilage.
The majority of cartilage and osteochondral tracking
studies reported in the literature have focused on
small animal models of cartilage injuries with the
mode of delivery mimicking MACI or MASI (matrix--
assisted chondrocyte or stem cell implantation). In
these systems, cells are localised to the injury site,
fixed in place and the degree of repair monitored
using a 7- or 11-T MRI scanner. These studies have
been successful in generating evidence of scaffold
failure and scaffold engraftment by understanding
MRI signal characteristics relating to particular events
and have also demonstrated evidence of engraftment
of stem cells to the defect site by MRI [14]. In our
opinion, it is not practical to design pre-clinical track-
ing approaches in small animal models to high
strength scanners knowing that such resolution will
not be achieved in pre-clinical veterinary scenario
when translating to clinically relevant large animals
such as sheep without substantial cost and capital in-
vestment. This is not to say that high-strength scan-
ners should not be used for small animal models as
they do undoubtedly offer a powerful means of gath-
ering data linked to mechanism of action, etc., in the
early stages of therapy development. It is also import-
ant to note that conclusions from this study were
drawn immediately from the 0.25-T veterinary MRI
scanner and only validated some time later on the
3-T clinical scanner and by histology. This supports
the application of this system as a practical means of
generating data in large animal pre-clinical studies
without the need for high-strength scanners. Further-
more, the larger extent of blooming seen on the
0.25-T images makes detection, if not localisation, of
the SPIONs easier without the capital costs associated
with the high-field MRI scanners.
Fig. 9 Immunohistochemical analysis at the synovial site 7 days post implantation in the a chronic and b acute injury models. Blue staining
(DAPI) represents cell nuclei whilst red fluorescence is significant of the DiI tag of implanted GET-Nanomag-labelled MSCs. Leukocytes, positive for
the CD45 marker, are stained green with Prussian blue staining highlighting the magnetic nanoparticle, Nanomag, and is seen as the black
staining in these monochrome images. Scale bars = 100 μm
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Conclusion
To conclude, this study demonstrates the feasibility of
tracking autologous MSCs in a large animal osteochon-
dral injury model using both low-field veterinary and
high-field clinical MRI scanners. We prove the use of
Nanomag in conjunction with the cell-penetrating pep-
tide system as a plausible tracking agent in cell-based
therapies. Finally, this study further demonstrates that
MSC cell behaviour and potency vary with treatment
regimens in clinical scenarios.
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